Citations (106)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Meghna Mehta, James Griffith, Janani Panneerselvam, Anish Babu, Jonathan Mani, Terence Herman, Rajagopal Ramesh & Anupama Munshi. (2021) Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage. International Journal of Radiation Biology 97:8, pages 1109-1120.
Read now
Read now
Ibrahim Halil Sahin, Elaine Tan & Richard Kim. (2021) Regorafenib, an investigational agent for the treatment of cholangiocarcinoma. Expert Opinion on Investigational Drugs 30:4, pages 333-341.
Read now
Read now
Teresa Macarulla, Clara Montagut, Francisco Javier Sánchez-Martin, Mónica Granja, Helena Verdaguer, Javier Sastre & Josep Tabernero. (2020) The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls. Expert Opinion on Biological Therapy 20:1, pages 15-22.
Read now
Read now
Danijel Galun, Tatjana Srdic-Rajic, Aleksandar Bogdanovic, Zlatibor Loncar & Marinko Zuvela. (2017) Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. Journal of Hepatocellular Carcinoma 4, pages 93-103.
Read now
Read now
Lorenza Rimassa, Tiziana Pressiani, Nicola Personeni & Armando Santoro. (2017) Regorafenib for the treatment of unresectable hepatocellular carcinoma. Expert Review of Anticancer Therapy 17:7, pages 567-576.
Read now
Read now
Jörg Trojan & Oliver Waidmann. (2016) Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. Journal of Hepatocellular Carcinoma 3, pages 31-36.
Read now
Read now
Oliver Waidmann & Jörg Trojan. (2015) Novel drugs in clinical development for hepatocellular carcinoma. Expert Opinion on Investigational Drugs 24:8, pages 1075-1082.
Read now
Read now
Sergei Boichuk, Jessica L Rausch & Anette Duensing. (2014) New developments in management of gastrointestinal stromal tumors: regorafenib, the new player in the team. Gastrointestinal Cancer: Targets and Therapy 4, pages 1-10.
Read now
Read now
Sujan Ravi & Ashwani K Singal. (2014) Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer. Core Evidence 9, pages 81-87.
Read now
Read now
Koh Miura, Masayuki Satoh, Makoto Kinouchi, Kuniharu Yamamoto, Yasuhiro Hasegawa, Alex Philchenkov, Yoichiro Kakugawa & Tsuneaki Fujiya. (2014) The preclinical development of regorafenib for the treatment of colorectal cancer. Expert Opinion on Drug Discovery 9:9, pages 1087-1101.
Read now
Read now
Paul Dent. (2014) Multi-kinase inhibition in ovarian cancer. Cancer Biology & Therapy 15:1, pages 1-2.
Read now
Read now
Joshua C Curtin. (2013) Novel drug discovery opportunities for colorectal cancer. Expert Opinion on Drug Discovery 8:9, pages 1153-1164.
Read now
Read now
Articles from other publishers (94)
Chen Huang, Xinli Ma, Ming Wang & Hui Cao. (2024) Drugs in the GIST Field (Therapeutic Targets and Clinical Trial Staging). Current Drug Delivery 21:1, pages 80-90.
Crossref
Crossref
Manmeet Kaur, Mandeep Kaur, Tania Bandopadhyay, Aditi Sharma, Anu Priya, Arvind Singh & Bubun Banerjee. (2023) Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs. Physical Sciences Reviews 8:10, pages 3393-3446.
Crossref
Crossref
Kyoo Hyun Kim, Minkyu Jung, Hyo Jin Lee, Su Jin Lee, Miso Kim, Mi Sun Ahn, Moon Young Choi, Na-Ri Lee & Sang Joon Shin. (2023) A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13). European Journal of Cancer, pages 113312.
Crossref
Crossref
Paulina Śledzińska, Marek Bebyn, Jacek Furtak, Agnieszka Koper & Krzysztof Koper. (2023) Current and promising treatment strategies in glioma. Reviews in the Neurosciences 34:5, pages 483-516.
Crossref
Crossref
Wei Peng, Xinhua Jiang, Weidong Zhang, Jianmin Hu, YaoJun Zhang & Ling Zhang. (2023) A radiomics-based model can predict recurrence-free survival of hepatocellular carcinoma after curative ablation. Asian Journal of Surgery 46:7, pages 2689-2696.
Crossref
Crossref
Nur Fadhilah Syahid, Natthida Weerapreeyakul & Tarapong Srisongkram. (2023) StackBRAF: A Large-Scale Stacking Ensemble Learning for BRAF Affinity Prediction. ACS Omega 8:23, pages 20881-20891.
Crossref
Crossref
Hao Yan, Wentong Wu, Yuhuai Hu, Jinjin Li, Jiangxin Xu, Xueqin Chen, Zhifei Xu, Xiaochun Yang, Bo Yang, Qiaojun He & Peihua Luo. (2023) Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. Nature Communications 14:1.
Crossref
Crossref
Zhen-Ling Liu, Huan-Huan Chen, Li-Li Zheng, Li-Ping Sun & Lei Shi. (2023) Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduction and Targeted Therapy 8:1.
Crossref
Crossref
Qiyuan Zhou, Shu Chen, Zoufeng Xu, Gongyuan Liu, Shuyuan Zhang, Zhigang Wang, Man‐Kit Tse, Shek‐Man Yiu & Guangyu Zhu. (2023) Multitargeted Platinum(IV) Anticancer Complexes Bearing Pyridinyl Ligands as Axial Leaving Groups. Angewandte Chemie International Edition 62:18.
Crossref
Crossref
Qiyuan Zhou, Shu Chen, Zoufeng Xu, Gongyuan Liu, Shuyuan Zhang, Zhigang Wang, Man‐Kit Tse, Shek‐Man Yiu & Guangyu Zhu. (2023) Multitargeted Platinum(IV) Anticancer Complexes Bearing Pyridinyl Ligands as Axial Leaving Groups. Angewandte Chemie 135:18.
Crossref
Crossref
Esmaeil Mohammadian, Tayebeh Oghabi Bakhshaiesh, Abolghasem Jouyban, Elahe Nazeri, Zaman Hasanvand, Setareh Moghimi, Rasoul Motahari, Loghman Firoozpour, Hamidreza Bijanzadeh, Mahmood Alizadeh Sani, Elaheh Hosseinzadeh, Rezvan Esmaeili & Alireza Foroumadi. (2022) Thienopyrimidine‐based agents bearing diphenylurea: Design, synthesis, and evaluation of antiproliferative and antiangiogenic activity. Archiv der Pharmazie 356:3.
Crossref
Crossref
Katja Kološa, Bojana Žegura, Martina Štampar, Metka Filipič & Matjaž Novak. (2023) Adverse Toxic Effects of Tyrosine Kinase Inhibitors on Non-Target Zebrafish Liver (ZFL) Cells. International Journal of Molecular Sciences 24:4, pages 3894.
Crossref
Crossref
Deepu Sharma, Fayyaz Rasool, Manjri Bharti, Komal M. Vyas & Sri Krishna Jayadev Magani. (2022) Regorafenib and Ruthenium Complex Combination Inhibit Cancer Cell Growth by Targeting PI3K/AKT/ERK Signalling in Colorectal Cancer Cells. International Journal of Molecular Sciences 24:1, pages 686.
Crossref
Crossref
Eduard Schmulenson, Cédric Bovet, Regula Theurillat, Laurent Arthur Decosterd, Carlo R. Largiadèr, Jean‐Christophe Prost, Chantal Csajka, Daniela Bärtschi, Matthias Guckenberger, Roger von Moos, Sara Bastian, Markus Joerger & Ulrich Jaehde. (2022) Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). British Journal of Clinical Pharmacology 88:12, pages 5336-5347.
Crossref
Crossref
Sameena Gul, Muhammad Faisal Maqbool, Amara Maryam, Muhammad Khan, Hafiz Abdullah Shakir, Muhammad Irfan, Chaman Ara, Yongming Li & Tonghui Ma. (2022) Vitamin K: A novel cancer chemosensitizer. Biotechnology and Applied Biochemistry 69:6, pages 2641-2657.
Crossref
Crossref
Pezhman Shiri, Sorour Ramezanpour, Ali Mohammad Amani & Wim Dehaen. (2022) A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy. Molecular Diversity 26:5, pages 2981-3002.
Crossref
Crossref
Nawaf A. Alsaif, Alaa Elwan, Mohammed M. Alanazi, Ahmad J. Obaidullah, Wael A. Alanazi, Abdullah F. Alasmari, Hussam Albassam, Hazem A. Mahdy & Mohammed S. Taghour. (2021) Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase. Molecular Diversity 26:4, pages 1915-1932.
Crossref
Crossref
Jing-Yu Hou, Ya-ting Xiao, Jing-Bo Huang, Xin-Hua Jiang, Kai Jiang, Xun Li, Li Xu & Min-Shan Chen. (2022) Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma. Frontiers in Pharmacology 13.
Crossref
Crossref
I-Cheng Lee, Yee Chao, Pei-Chang Lee, San-Chi Chen, Chen-Ta Chi, Chi-Jung Wu, Kuo-Cheng Wu, Ming-Chih Hou & Yi-Hsiang Huang. (2022) Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma. Cancers 14:8, pages 2014.
Crossref
Crossref
Aleksandra Sochacka-Ćwikła, Marcin Mączyński & Andrzej Regiec. (2022) FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. Molecules 27:7, pages 2259.
Crossref
Crossref
Blanca Cucarull, Anna Tutusaus, Patricia Rider, Tania Hernáez-Alsina, Carlos Cuño, Pablo García de Frutos, Anna Colell, Montserrat Marí & Albert Morales. (2022) Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers 14:3, pages 621.
Crossref
Crossref
Tomas Koltai, Stephan Joel Reshkin & Rosa Angela Cardone. 2022. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy
147
197
.
Sangmin Jung, Hyeonsu Jo, Sujin Hyung & Noo Li Jeon. 2022. Microfluidics and Biosensors in Cancer Research. Microfluidics and Biosensors in Cancer Research
231
256
.
Sareshma Sudhesh Dev, Syafiq Asnawi Zainal Abidin, Reyhaneh Farghadani, Iekhsan Othman & Rakesh Naidu. (2021) Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer. Frontiers in Pharmacology 12.
Crossref
Crossref
Merzak Doulache, S. Irem Kaya, Ahmet Cetinkaya, Nurgul K Bakirhan, Mohamed Trari & Sibel A. Ozkan. (2021) Detailed electrochemical behavior and thermodynamic parameters of anticancer drug regorafenib and its sensitive electroanalytical assay in biological and pharmaceutical samples. Microchemical Journal 170, pages 106717.
Crossref
Crossref
Lisha Mou, Xiaohe Tian, Bo Zhou, Yongqiang Zhan, Jiao Chen, Ying Lu, Jing Deng, Ying Deng, Zijing Wu, Qi Li, Yi’an Song, Hongyuan Zhang, Jinjun Chen, Kuifeng Tian, Yong Ni & Zuhui Pu. (2021) Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials. Frontiers in Oncology 11.
Crossref
Crossref
Tuğba GÜNGÖR, Tuncay KARAKURT & Zarife Sibel ŞAHİN. (2021) Synthesis, Spectroscopic Characterization, Crystal Structure and Theoretical Studies on New Organic Single Crystal of 1-(3,5-Difluorophenyl)-3-(2-Nitrophenyl)Urea. Celal Bayar Üniversitesi Fen Bilimleri Dergisi 17:3, pages 285-295.
Crossref
Crossref
Vahid Mansouri, Nima Beheshtizadeh, Maliheh Gharibshahian, Leila Sabouri, Mohammad Varzandeh & Nima Rezaei. (2021) Recent advances in regenerative medicine strategies for cancer treatment. Biomedicine & Pharmacotherapy 141, pages 111875.
Crossref
Crossref
Jung Suk Kim, Jung Hyun Cho & Han‐Gon Choi. (2021)
Development of a Simple, Precise, and Validated
HPLC
Method for the Anticancer Drug, Regorafenib: Application to Pharmacokinetics in Rats and Stability Study
. Bulletin of the Korean Chemical Society 42:9, pages 1239-1244.
Crossref
Crossref
Kouichi Yanagi, Toru Komatsu, Shusuke Ogihara, Takayoshi Okabe, Hirotatsu Kojima, Tetsuo Nagano, Tasuku Ueno, Kenjiro Hanaoka & Yasuteru Urano. (2021) Establishment of live-cell-based coupled assay system for identification of compounds to modulate metabolic activities of cells. Cell Reports 36:1, pages 109311.
Crossref
Crossref
Umar Faruq Chowdhury, Abdullah Al Saba, Abu Sufian Sufi, Akib Mahmud Khan, Ishrat Sharmin, Aziza Sultana & Md Ohedul Islam. (2021) Subtractive proteomics approach to Unravel the druggable proteins of the emerging pathogen Waddlia chondrophila and drug repositioning on its MurB protein. Heliyon 7:6, pages e07320.
Crossref
Crossref
Ghada H. Al-Ansary, Tamer Nasr, Heba Taha, Walid Fayad & Shahenda Mahgoub. (2021) Biphenylurea/thiourea derivatives tagged with heteroarylsulfonamide motifs as novel VEGFR2 inhibitors; Design, synthesis and anti-angiogenic activity. Bioorganic Chemistry 107, pages 104640.
Crossref
Crossref
Yi Zhang, Antonio Solinas, Stefano Cairo, Matthias Evert, Xin Chen & Diego F. Calvisi. (2021) Molecular Mechanisms of Hepatoblastoma. Seminars in Liver Disease 41:01, pages 028-041.
Crossref
Crossref
Giovanni Galati, Antonio Fabio Massimo Vainieri, Claudia Angela Maria Fulgenzi, Stefano Di Donato, Marianna Silletta, Paolo Gallo, Angelo Onorato, Umberto Vespasiani-Gentilucci & Antonio Picardi. (2020) Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. Current Drug Metabolism 21:11, pages 866-884.
Crossref
Crossref
Xiang Li, Guangwei He, Feng Su, Zhaoxing Chu, Leiming Xu, Yazhong Zhang, Jianping Zhou & Yang Ding. (2020) Regorafenib-loaded poly (lactide-co-glycolide) microspheres designed to improve transarterial chemoembolization therapy for hepatocellular carcinoma. Asian Journal of Pharmaceutical Sciences 15:6, pages 739-751.
Crossref
Crossref
Divya Subramonian, Nikki Phanhthilath, Hannah Rinehardt, Sean Flynn, Yuchen Huo, Jing Zhang, Karen Messer, Qianxing Mo, Shixia Huang, Jacqueline Lesperance & Peter E. Zage. (2020) Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. British Journal of Cancer 123:4, pages 568-579.
Crossref
Crossref
Patrick Roser, Jörn Weisner, Juliane Stehle, Daniel Rauh & Malte Drescher. (2020)
Conformational selection
vs.
induced fit: insights into the binding mechanisms of p38α MAP Kinase inhibitors
. Chemical Communications 56:62, pages 8818-8821.
Crossref
Crossref
Daiki Taguchi, Masahiro Inoue, Koji Fukuda, Taichi Yoshida, Kazuhiro Shimazu, Kazuma Fujita, Hiroyuki Okuyama, Nobuhisa Matsuhashi, Akihito Tsuji, Kazuhiro Yoshida, Masatomo Miura & Hiroyuki Shibata. (2019) Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities. International Journal of Clinical Oncology 25:4, pages 531-540.
Crossref
Crossref
Tomomi Hashiba, Taro Yamashita, Hikari Okada, Kouki Nio, Takehiro Hayashi, Yoshiro Asahina, Tomoyuki Hayashi, Takeshi Terashima, Noriho Iida, Hajime Takatori, Tetsuro Shimakami, Kazunori Kawaguchi, Kuniaki Arai, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Hiroyuki Takamura, Tetsuo Ohta, Masao Honda & Shuichi Kaneko. (2020) Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology 10:2, pages 269-285.
Crossref
Crossref
Samantha M. Ervin, Ronan P. Hanley, Lauren Lim, William G. Walton, Kenneth H. Pearce, Aadra P. Bhatt, Lindsey I. James & Matthew R. Redinbo. (2019) Targeting Regorafenib-Induced Toxicity through Inhibition of Gut Microbial β-Glucuronidases. ACS Chemical Biology 14:12, pages 2737-2744.
Crossref
Crossref
Aneta L. Zygulska. 2019. Multidisciplinary Approach for Colorectal Cancer. Multidisciplinary Approach for Colorectal Cancer.
Ae Kyung Park, Ji Yeoun Lee, Heesun Cheong, Vijay Ramaswamy, Sung-Hye Park, Marcel Kool, Ji Hoon Phi, Seung Ah Choi, Florence Cavalli, Michael D. Taylor & Seung-Ki Kim. (2019) Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma. BMC Cancer 19:1.
Crossref
Crossref
Lars Henrik Jensen, René Olesen, Lone Noergaard Petersen, Anders Kindberg Boysen, Rikke Fredslund Andersen, Jan Lindebjerg, Lise Nottelmann, Caroline Emilie Brenner Thomsen, Birgitte Mayland Havelund, Anders Jakobsen & Torben Frøstrup Hansen. (2019) NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer. Cancers 11:11, pages 1649.
Crossref
Crossref
Ganfeng Xie, Yuzhu Gong, Shuang Wu, Chong Li, Songtao Yu, Zhe Wang, Jianfang Chen, Quanfeng Zhao, Jianjun Li & Houjie Liang. (2019) Meta-Analysis of Regorafenib-Associated Adverse Events and Their Management in Colorectal and Gastrointestinal Stromal Cancers. Advances in Therapy 36:8, pages 1986-1998.
Crossref
Crossref
Alessio Amatu, Marta Schirripa, Federica Tosi, Sara Lonardi, Katia Bencardino, Erica Bonazzina, Laura Palmeri, Damiano Alfio Patanè, Elio Gregory Pizzutilo, Benedetta Mussolin, Francesca Bergamo, Giulia Alberti, Rossana Intini, Letizia Procaccio, Marco Arese, Silvia Marsoni, Michele Nichelatti, Vittorina Zagonel, Salvatore Siena, Alberto Bardelli, Fotios Loupakis, Federica Di Nicolantonio, Andrea Sartore-Bianchi & Ludovic Barault. (2019) High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Frontiers in Oncology 9.
Crossref
Crossref
Ajaikumar B Kunnumakkara, Devivasha Bordoloi, Bethsebie Lalduhsaki Sailo, Nand Kishor Roy, Krishan Kumar Thakur, Kishore Banik, Mehdi Shakibaei, Subash C Gupta & Bharat B Aggarwal. (2019) Cancer drug development: The missing links. Experimental Biology and Medicine 244:8, pages 663-689.
Crossref
Crossref
Patrick Roser, Jörn Weisner, Jeffrey R. Simard, Daniel Rauh & Malte Drescher. (2018) Direct monitoring of the conformational equilibria of the activation loop in the mitogen-activated protein kinase p38α. Chemical Communications 54:85, pages 12057-12060.
Crossref
Crossref
Jianxin Chen & Junhui Wang. (2018) Risk of regorafenib-induced cardiovascular events in patients with solid tumors. Medicine 97:41, pages e12705.
Crossref
Crossref
Qiumeng Zhang, Qianqian Shen, Lixin Gao, Linjiang Tong, Jia Li, Yi Chen & Wei Lu. (2018) Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine derivatives as new multi-targeted inhibitors of Aurora A/B and KDR. European Journal of Medicinal Chemistry 158, pages 428-441.
Crossref
Crossref
Xiao-xiao He, Liang-liang Shi, Meng-jun Qiu, Qiu-ting Li, Meng-meng Wang, Zhi-fan Xiong & Sheng-li Yang. (2018) Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families. Biochemical and Biophysical Research Communications 504:4, pages 878-884.
Crossref
Crossref
Xiu Hu, Lin-wen Wu, Zuo-yan Zhang, Meng-ling Chen, Yang-ling Li & Chong Zhang. (2018) The anti-tumor effect of regorafenib in lung squamous cell carcinoma in vitro. Biochemical and Biophysical Research Communications 503:2, pages 1123-1129.
Crossref
Crossref
V. V. Breder, M. U. Pitkevich, E. R. Virshke, L. A. Kostyakova, I. A. Dzhanyan & K. K. Laktionov. (2018) BCLC-B hepatocellular carcinoma treatment or when should the systemic therapy be started. Medical Council:10, pages 27-32.
Crossref
Crossref
Torsten Zimmermann, Joachim Höchel, Michael Becka, Michael K. Boettger, Beate Rohde, Barbara Schug, Kathleen S. Kunert & Frank Donath. (2018) Topical administration of regorafenib eye drops: phase I dose‐escalation study in healthy volunteers. British Journal of Clinical Pharmacology 84:5, pages 865-875.
Crossref
Crossref
Masatoshi Kudo. (2018) Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma. Liver Cancer 7:2, pages 123-133.
Crossref
Crossref
Jane L. Roberts, Andrew Poklepovic & Laurence Booth. (2017) Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species. Oncotarget 8:59, pages 99451-99469.
Crossref
Crossref
Bin Zhao & Hong Zhao. (2017) Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib. Oncotarget 8:55, pages 93813-93824.
Crossref
Crossref
Bin Zhao & Hong Zhao. (2017) Incidence and risk of regorafenib-induced hepatotoxicity. Oncotarget 8:48, pages 84102-84111.
Crossref
Crossref
Krittiya Korphaisarn, Jonathan M. Loree, Van Nguyen, Ryanne Coulson, Vijaykumar Holla, Beate C. Litzenburger, Ken Chen, Gordon B. Mills, Dipen M. Maru, Funda Meric-Bernstan, Kenna R. Mills Shaw & Scott Kopetz. (2017) Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. Oncotarget 8:34, pages 57882-57888.
Crossref
Crossref
Xiurong Hu, Mengying Sun, Yang Li & Guping Tang. (2017) Evaluation of molecular chaperone drug function: Regorafenib and β-cyclodextrins. Colloids and Surfaces B: Biointerfaces 153, pages 61-68.
Crossref
Crossref
Marcus Tuchen, Annette Wilisch-Neumann, Evelyn A. Daniel, Lisa Baldauf, Doreen Pachow, Johannes Scholz, Frank Angenstein, Oliver Stork, Elmar Kirches & Christian Mawrin. (2017) Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells. European Journal of Cancer 73, pages 9-21.
Crossref
Crossref
Salvatore Del Prete, Gregorio Cennamo, Luigi Leo, Liliana Montella, Bruno Vincenzi, Maria Biglietto, Francesca Andreozzi, Antonella Prudente, Patrizia Iodice, Clementina Savastano, Anna Nappi, Vincenzo Montesarchio & Raffaele Addeo. (2017) Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study. Future Oncology 13:5, pages 415-423.
Crossref
Crossref
Ramesh Jayaprakash & Senthil Kumar Natesan. (2017) A Validated Stability Indicating RP-HPLC Method for the Estimation of an Anti-Cancer Drug Regorafenib in Pure and Pharmaceutical Dosage Form. Journal of Pharmaceutical Chemistry 4:1, pages 5-10.
Crossref
Crossref
Ziwei Zhou, Herui Yao & Hai Hu. 2017. Translational Research in Breast Cancer. Translational Research in Breast Cancer
171
195
.
Massimiliano Berretta, Luca Rinaldi, Fabrizio Di Benedetto, Arben Lleshi, Vallì De Re, Gaetano Facchini, Paolo De Paoli & Raffaele Di Francia. (2016) Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. Frontiers in Pharmacology 7.
Crossref
Crossref
Dieter Zopf, Iduna Fichtner, Ajay Bhargava, Wolfram Steinke, Karl‐Heinz Thierauch, Konstanze Diefenbach, Scott Wilhelm, Frank‐Thorsten Hafner & Michael Gerisch. (2016) Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. Cancer Medicine 5:11, pages 3176-3185.
Crossref
Crossref
Cristina Mirantes, Maria Alba Dosil, N?ria Eritja, Isidre Felip, S?nia Gatius, Maria Santacana, Xavier Matias-Guiu & Xavier Dolcet. (2016) Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias. European Journal of Cancer 63, pages 74-87.
Crossref
Crossref
Helena Verdaguer, Josep Tabernero & Teresa Macarulla. (2016) Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Therapeutic Advances in Medical Oncology 8:3, pages 230-242.
Crossref
Crossref
Meng-Ying Sun, Su-Xiang Wu, Xin-Bo Zhou, Jian-Ming Gu & Xiu-Rong Hu. (2016) Comparison of the crystal structures of the potent anticancer and anti-angiogenic agent regorafenib and its monohydrate. Acta Crystallographica Section C Structural Chemistry 72:4, pages 291-296.
Crossref
Crossref
Li-Mei Wang, Bao-Quan Du, Da-Zhuang Zuo, Ming-Ke Cheng, Meng Zhao, Si-Jia Zhao, Xin Zhai & Ping Gong. (2015) An efficient and high-yielding protocol for the production of Regorafenib via a new synthetic strategy. Research on Chemical Intermediates 42:4, pages 3209-3218.
Crossref
Crossref
Yishay Wasserstrum, Ran Kornowski, Pia Raanani, Avi Leader, Oren Pasvolsky & Zaza Iakobishvili. (2015) Hypertension in cancer patients treated with anti-angiogenic based regimens. Cardio-Oncology 1:1.
Crossref
Crossref
Matthew D. Hellmann, Isrid Sturm, Zuzana Jirakova Trnkova, John Lettieri, Konstanze Diefenbach, Naiyer A. Rizvi & Scott N. Gettinger. (2015) Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancers. Clinical Lung Cancer 16:6, pages 514-522.
Crossref
Crossref
Li-Ching Fan, Hao-Wei Teng, Chung-Wai Shiau, Wei-Tien Tai, Man-Hsin Hung, Shung-Haur Yang, Jeng-Kai Jiang & Kuen-Feng Chen. (2015) Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer. Neoplasia 17:9, pages 687-696.
Crossref
Crossref
Matt Shirley & Gillian M. Keating. (2015) Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours. Drugs 75:9, pages 1009-1017.
Crossref
Crossref
Ning Wei, Edward Chu, Shao-yu Wu, Peter Wipf & John C. Schmitz. (2014) The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells. Oncotarget 6:7, pages 4745-4756.
Crossref
Crossref
Yoonjin Kwak, Soo Kyung Nam, An Na Seo, Duck-Woo Kim, Sung-Bum Kang, Woo Ho Kim & Hye Seung Lee. (2015) Fibroblast Growth Factor Receptor 1 Gene Copy Number and mRNA Expression in Primary Colorectal Cancer and Its Clinicopathologic Correlation. Pathobiology 82:2, pages 76-83.
Crossref
Crossref
Antonio Russo, Antonio Galvano, Giuseppe Bronte & Marc Peeters. 2015. Targeted Therapies for Solid Tumors. Targeted Therapies for Solid Tumors
147
162
.
Wei-Tien Tai, Pei-Yi Chu, Chung-Wai Shiau, Yao-Li Chen, Yong-Shi Li, Man-Hsin Hung, Li-Ju Chen, Pei-Lung Chen, Jung-Chen Su, Ping-Yi Lin, Hui-Chuan Yu & Kuen-Feng Chen. (2014) STAT3 Mediates Regorafenib-Induced Apoptosis in Hepatocellular Carcinoma. Clinical Cancer Research 20:22, pages 5768-5776.
Crossref
Crossref
Dongshi Chen, Liang Wei, Jian Yu & Lin Zhang. (2014) Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis. Clinical Cancer Research 20:13, pages 3472-3484.
Crossref
Crossref
Annett Maderer, Stanislav Plutizki, Jan-Peter Kramb, Katrin Göpfert, Monika Linnig, Katrin Khillimberger, Christopher Ganser, Eva Lauermann, Gerd Dannhardt, Peter R. Galle & Markus Moehler. (2014) Moguntinones—New Selective Inhibitors for the Treatment of Human Colorectal Cancer. Molecular Cancer Therapeutics 13:6, pages 1399-1409.
Crossref
Crossref
Hong X. Ding, Carolyn A. Leverett, Robert E. KyneJr.Jr., Kevin K.-C. Liu, Subas M. Sakya, Andrew C. Flick & Christopher J. O’Donnell. (2014) Synthetic approaches to the 2012 new drugs. Bioorganic & Medicinal Chemistry 22:7, pages 2005-2032.
Crossref
Crossref
Zexing Wang, Jing Xu, Weiwei Nie, Guichun Huang, Jinhai Tang & Xiaoxiang Guan. (2013) Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis. European Journal of Clinical Pharmacology 70:2, pages 225-231.
Crossref
Crossref
Valentina Grossi. (2014) p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance. World Journal of Gastroenterology 20:29, pages 9744.
Crossref
Crossref
A. Mortlock, K. Foote, J. Kettle & B. Aquila. 2014. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering.
Giuseppe Giaccone & Jean-Charles SoriaSophie Postel-Vinay & Jean-Pierre Armand. 2013. Targeted Therapies in Oncology, Second Edition. Targeted Therapies in Oncology, Second Edition
283
314
.
Colette Dissous, Mathieu Vanderstraete, Svenja Beckmann, Nadège Gouignard, Silke Leutner, Christin Buro & Christoph G. Grevelding. 2013. Protein Phosphorylation in Parasites. Protein Phosphorylation in Parasites
337
356
.
Rosalba D’Alessandro, Maria G. Refolo, Catia Lippolis, Caterina Messa, Aldo Cavallini, Roberta Rossi, Leonardo Resta, Antonio Di Carlo & Brian I. Carr. (2013) Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemotherapy and Pharmacology 72:4, pages 869-877.
Crossref
Crossref
Viswanath Reddy Belum, Shenhong Wu & Mario E. Lacouture. (2013) Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Investigational New Drugs 31:4, pages 1078-1086.
Crossref
Crossref
Giuseppe Aprile, Marianna Macerelli & Francesco Giuliani. (2013) Regorafenib for Gastrointestinal Malignancies. BioDrugs 27:3, pages 213-224.
Crossref
Crossref
Hans Prenen, Loredana Vecchione & Eric Van Cutsem. (2013) Role of targeted agents in metastatic colorectal cancer. Targeted Oncology 8:2, pages 83-96.
Crossref
Crossref
Serge Y. Fuchs. (2013) Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy. Journal of Interferon & Cytokine Research 33:4, pages 211-225.
Crossref
Crossref
Damien Gerald, Sudhakar Chintharlapalli, Hellmut G. Augustin & Laura E. Benjamin. (2013) Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy. Cancer Research 73:6, pages 1649-1657.
Crossref
Crossref
Clifton Ming Tay, Chee Wee Ong, Victor Kwan Min Lee & Brendan Pang. (2013) KIT gene mutation analysis in solid tumours: biology, clincial applications and trends in diagnostic reporting. Pathology 45:2, pages 127-137.
Crossref
Crossref
Olivier Bouché & Pierre Laurent-PuigR. Coriat, P. Boudou-Rouquette & F. Goldwasser. 2013. Médecine personnalisée en cancérologie digestive. Médecine personnalisée en cancérologie digestive
305
313
.
Sabine TejparHans PrenenMassimiliano Mazzone. (2012) Overcoming Resistance to Antiangiogenic Therapies. The Oncologist 17:8, pages 1039-1050.
Crossref
Crossref